Business Wire

Vista Entertainment Solutions Appoints Till Cussmann to Pivotal New Executive Role

Share

Vista Entertainment Solutions (‘Vista Cinema’), the leading provider of cinema management software for global cinema exhibition and the founding company of Vista Group International (NZX & ASX: VGL), has appointed Till Cussmann Senior Vice President Sales for EMEA and General Manager, Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180508006843/en/

Till Cussman joins Vista Entertainment Solutions (Photo Business Wire)

Till Cussman joins Vista Entertainment Solutions (Photo Business Wire)

With the company’s customer base growing fast as opportunities on the continent are realised, Till will lead the next phase of growth for Vista Cinema in Europe. He will focus on sales management and customer relationships in the whole of the EMEA region as well as on general management of the continental European activities.

Over a decade, Till Cussmann was deeply involved in the digital conversion of movie theatres as well as the technical conception and implementation of infrastructure for new venues. Previously, as Senior Vice President of CinemaNext and its predecessor dcinex, he was responsible for the overall product and customer support strategy, geographical expansion to more than 20 countries and he led re-shaping the organization from a server manufacturer to a one-stop-shop for cinema technology. Till also has experience in the marketing of technical products in the leisure and retail industry.

Till will share his time between continental Europe and the Vista Cinema EMEA headquarters in London. He will report to Mischa Kay, Managing Director of Vista Entertainment Solutions EMEA.

“I’m delighted to join Vista Group and take part in the next level of success of Vista’s great products in Europe,” says Till Cussmann. “I strongly believe that an intelligent cinema management system is at the heart of any cinema operation and will be more and more a significant factor in an exhibitor’s business success. Vista Cinema’s product line is by far the most advanced and complete solution for cinemas on the market and I’m thankful that Vista Group gives me this great opportunity. I’m particularly excited about joining a great team of skilled people passionate about cinema.”

“With the appointment of Till Cussmann, Vista solidifies its plan to become even closer to our European customers and ensure they benefit from the best possible advice, support and attention,” says Mischa Kay, Managing Director EMEA. “With Till’s deep understanding and experience in the cinema and retail industry as well as his strong network, we are convinced we will fulfill our European customer’s expectations delivering to them the best possible service.”

For the first time, Vista will be exhibiting at the German movie theatre convention Kino Kongress 2018 in Baden-Baden from May 15th to 17th. “With our recent success in Austria and Germany, and with Till on board,” continued Kay, “we are in the best position to serve additional customer’s in the German speaking territories and expand our regional footprint in Europe including existing markets such as France, Italy and Spain.”

Visit Vista at Kino Baden-Baden; booth 302 on the 1st level of the exhibition floor.

About Vista Entertainment Solutions

Vista Entertainment Solutions Ltd (‘Vista Cinema’) is the world leader in cinema management software solutions with installations in more than 90 countries around the world and an estimated 38% global market share in the Large Cinema Circuit market. The Vista Cinema software product line comprises multiple modules, integrated and scalable, suited to cinema exhibitors operating 20+ screens and 100s of cinemas. Vista Cinema is headquartered in Auckland, New Zealand, and has subsidiaries incorporated in Los Angeles, London, Shanghai, Beijing, Cape Town and Mexico City.

Website: www.vista.co
Twitter: @VistaCinema
LinkedIn: www.linkedin.com/company/vista-entertainment-solutions

Contact information

Vista Entertainment Solutions, EMEA/London, UK
Sharon Heideman, +44 7720 591 196
sharon.heideman@vista.co
or
Vista Group International/Auckland, NZ
Christine Fenby, +64 21 727 006
christine.fenby@vista.co

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CESTPress release

Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the

iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CESTPress release

iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g

Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects23.7.2019 06:00:00 CESTPress release

Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality. Jonathan Goldman, MD, Abzena CEO added: “Abzena believes in patient first drug development. Our expertise and experience with Synaffix GlycoConnect™ and HydraSpace™ technology further advances our leadership across multiple platforms in ADC. We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.” About Abzena Abzena provides the most complete set of solutions in integrated discover

Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size23.7.2019 01:30:00 CESTPress release

Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/ Picture of 1mm squared die of silicon CMOS based smell sensor, with dog nose equivalent ~1,200 sensor pixels (Photo: Business Wire) Aroma Bit: http://www.aromabit.com Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Micro

Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth23.7.2019 01:00:00 CESTPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005781/en/ Logitech delivers a strong start to Fiscal Year 2020 with robust sales and profit growth. (Graphic: Business Wire) Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP operating income grew 46 percent to $47 million, compared to $32 million in the same quarter a year ago. Q1 GAAP earnings per share (EPS) grew 17 percent to $0.27, compared to $0.23 in the same quarter a year ago. Q1 non-GAAP operating income grew 11 percent to $67 million, compared to $61 million in the same quarter a year ago. Q1 non-GAAP EPS grew 15 percent to $0.39, compared to $0.34 in the same quarter a year ago. Cash flow from operations was $37 million, compared to $12 million in the sa

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an